Vical (NASDAQ: VICL) is one of 295 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Vical to related businesses based on the strength of its risk, dividends, earnings, profitability, analyst recommendations, valuation and institutional ownership.
This is a breakdown of current ratings for Vical and its competitors, as provided by MarketBeat.
||Strong Buy Ratings
Vical presently has a consensus target price of $9.00, suggesting a potential upside of 309.09%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 38.25%. Given Vical’s stronger consensus rating and higher possible upside, analysts clearly believe Vical is more favorable than its competitors.
This table compares Vical and its competitors’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Valuation and Earnings
This table compares Vical and its competitors revenue, earnings per share (EPS) and valuation.
Vical’s competitors have higher revenue and earnings than Vical. Vical is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Volatility & Risk
Vical has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500. Comparatively, Vical’s competitors have a beta of 6.66, suggesting that their average share price is 566% more volatile than the S&P 500.
Insider & Institutional Ownership
23.5% of Vical shares are held by institutional investors. Comparatively, 50.5% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 5.9% of Vical shares are held by insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Vical Company Profile
Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, and completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.
Receive News & Ratings for Vical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.